Newamsterdam Pharma Company N.V. ( (NAMS) ) has released its Q1 earnings. Here is a breakdown of the information Newamsterdam Pharma Company N.V. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
NewAmsterdam Pharma Company N.V. is a late-stage biopharmaceutical company based in the Netherlands, focusing on developing therapies for cardiometabolic diseases, with a primary emphasis on their CETP inhibitor, obicetrapib, aimed at lowering LDL-C levels in patients where current treatments are inadequate.